SR One, a trans-Atlantic biotech venture capital firm, closed its first independent fund, having recently completed its spinout from GlaxoSmithKline (GSK).
GSK is the largest investor in the $500m fund, joined by a global pool of institutional asset managers, endowments, foundations, pension funds and family offices.
Based in San Francisco, CA, and London, UK, SR One will seek to continue to build elite biotechnology companies developing innovative medicines that address significant unmet needs.
Led by Chief Executive Officer, Simeon George, SR One will continue building and investing in next-generation biotechnology companies translating science into new medicines.
Simeon George, M.D., M.B.A, has 15 years of experience in the biotechnology industry. He joined SR One in 2007 and established the San Francisco office in 2010. Simeon earned his M.D. and M.B.A. from the University of Pennsylvania School of Medicine / Wharton and B.A. from Johns Hopkins University. Previously, he worked in management consulting (Bain & Co.) and investment banking (Goldman Sachs). Simeon led SR One’s investments in several marquee deals including CRISPR Therapeutics (CRSP), Principia Biopharma (PRNB, recently acquired by Sanofi for $3.7bn), Turning Point Therapeutics (TPTX), Progyny (PGNY) and Nkarta Therapeutics (NKTX), which he cofounded.
Goldman Sachs acted as the sole global placement agent for the fundraise. Kirkland & Ellis acted as counsel to SR One for the fundraise.
FinSMEs
24/11/2020